TY - JOUR
T1 - Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
AU - Gaughran, Fiona Patricia
AU - Stringer, Dominic
AU - Berk, Michael
AU - Smith, Shubulade Mary Eniola
AU - Taylor, David Michael
AU - Whiskey, Eromona
AU - Landau, Sabine
AU - Murray, Robin MacGregor
AU - McGuire, Philip
AU - Gardner-Sood, Poonam
AU - Wojewodka, Gabriella Monika
AU - Ciufolini, Simone
AU - Jordan, Harriet Isabel
AU - Clarke, Jessie
AU - Allen, Lauren Elizabeth
AU - Krivoy, Amir
AU - Stubbs, Brendon
AU - Lowe, Phillipa
AU - Arbuthnott, Maurice
AU - Rathod, Shanaya
AU - Boardman, Andrew
AU - Firdosi, Mudasir
AU - McGrath, John J.
PY - 2020/1/6
Y1 - 2020/1/6
N2 - Background: People experiencing their first episode of psychosis are often deficient in vitamin D. Observational studies have reported an association between low vitamin D concentrations and poorer subsequent health outcomes in psychosis. A vitamin D deficiency in neonates and children has been linked to a later increased risk of schizophrenia and psychotic-like experiences. This trial aims to examine the effect of high-dose vitamin D supplementation on outcomes in early psychosis. We hypothesise that vitamin D supplementation will be associated with better mental health outcomes. Methods/design: The DFEND study is a multicentre double-blind placebo-controlled parallel-group trial of vitamin D supplementation in people with early psychosis. Patients with an ICD-10 diagnosis of functional psychosis will be randomised in a 1:1 ratio to receive either 120,000 IU/month of vitamin D (cholecalciferol) or a matched placebo for 6 months. The primary outcome is the total Positive and Negative Syndrome Scale (PANSS) score at the 6-month follow-up for all patients. Secondary outcomes include assessment of mood (Calgary Depression Scale), general function (Global Assessment of Functioning), cardiovascular risk (body mass index, waist circumference, C-reactive protein, cholesterol and HbA1c) and vitamin D levels at the 6-month follow-up. Additionally, 3- and 6-month total PANSS scores will be analysed for those with inadequate vitamin D levels at the baseline. Discussion: The DFEND study is the first trial to examine whether vitamin D supplementation in early psychosis is associated with better mental health outcomes. The findings of this study may help to resolve the clinical equipoise regarding the benefits and cost-effectiveness of routine vitamin D supplementation in people with psychosis. Trial registration: ISRCTN, ISRCTN12424842. Registered on 25 February 2015.
AB - Background: People experiencing their first episode of psychosis are often deficient in vitamin D. Observational studies have reported an association between low vitamin D concentrations and poorer subsequent health outcomes in psychosis. A vitamin D deficiency in neonates and children has been linked to a later increased risk of schizophrenia and psychotic-like experiences. This trial aims to examine the effect of high-dose vitamin D supplementation on outcomes in early psychosis. We hypothesise that vitamin D supplementation will be associated with better mental health outcomes. Methods/design: The DFEND study is a multicentre double-blind placebo-controlled parallel-group trial of vitamin D supplementation in people with early psychosis. Patients with an ICD-10 diagnosis of functional psychosis will be randomised in a 1:1 ratio to receive either 120,000 IU/month of vitamin D (cholecalciferol) or a matched placebo for 6 months. The primary outcome is the total Positive and Negative Syndrome Scale (PANSS) score at the 6-month follow-up for all patients. Secondary outcomes include assessment of mood (Calgary Depression Scale), general function (Global Assessment of Functioning), cardiovascular risk (body mass index, waist circumference, C-reactive protein, cholesterol and HbA1c) and vitamin D levels at the 6-month follow-up. Additionally, 3- and 6-month total PANSS scores will be analysed for those with inadequate vitamin D levels at the baseline. Discussion: The DFEND study is the first trial to examine whether vitamin D supplementation in early psychosis is associated with better mental health outcomes. The findings of this study may help to resolve the clinical equipoise regarding the benefits and cost-effectiveness of routine vitamin D supplementation in people with psychosis. Trial registration: ISRCTN, ISRCTN12424842. Registered on 25 February 2015.
KW - 25OHD
KW - First episode
KW - Mental health
KW - Positive and Negative Syndrome Scale
KW - Psychosis
KW - Randomised controlled trial
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=85077599059&partnerID=8YFLogxK
U2 - 10.1186/s13063-019-3758-9
DO - 10.1186/s13063-019-3758-9
M3 - Article
SN - 1745-6215
VL - 21
JO - Trials
JF - Trials
IS - 1
M1 - 14
ER -